Cancers, Vol. 11, Pages 125: Influence of Vitamin D in Advanced Non-Small Cell Lung Cancer Patients Treated with Nivolumab

Cancers, Vol. 11, Pages 125: Influence of Vitamin D in Advanced Non-Small Cell Lung Cancer Patients Treated with Nivolumab Cancers doi: 10.3390/cancers11010125 Authors: Jessica Cusato Carlo Genova Cristina Tomasello Paolo Carrega Selene Ottonello Gabriella Pietra Maria Mingari Irene Cossu Erika Rijavec Anna Leggieri Giovanni Perri Maria Bello Simona Coco Simona Boccardo Guido Ferlazzo Francesco Grossi Antonio D’Avolio Nivolumab is one of the most commonly used monoclonal antibodies for advanced non-small cell lung cancer treatment, to the extent that the presence of its anti-antibody is considered a negative prognostic factor. Vitamin D (VD) modulates expression of the genes involved in drug metabolism and elimination. Immune system regulation and immunodeficiency is frequent in non-small cell lung cancer patients. To date, no data have been reported about the relationship between nivolumab and VD. The aim of this study was to quantify plasma 25-hydroxyVD (25-VD) and 1,25-VD, nivolumab, and its anti-antibody before starting treatment (baseline) and at 15, 45 and 60 days of therapy. VD-pathway-associated gene single nucleotide polymorphisms (SNPs) were also evaluated. Molecules were quantified through enzyme-linked immunosorbent assay, and SNPs through real-time PCR. Forty-five patients were enrolled. Median nivolumab concentrations were 12.5 ug/mL, 22.3 ug/mL and 27.1 ug/mL at 15, 45 and 60 days respectively. No anti-nivolumab antibod...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research